Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone. I am joined today by Joe Schifoni, Chief Executive Officer, Pat Berry, Chief Commercial Officer, and Ryan Previn, Chief Financial Officer. We're also joined by Christian Heidretter, our Chief Scientific Officer. Before we begin, I need to remind everyone that on today's call, we may make forward-looking statements that are subject to risks and uncertainties, and that actual results may differ materially. we list the factors that may cause our results to be materially different here on slide two of this presentation. We also may refer to non-GAAP measures, the reconciliations for which may also be found in the appendix to this presentation that is now posted on our website at Endeavor.com. I'll now turn the call over to Joe Schifone, our CEO. Thanks, Jason, and good morning and thank you for joining us on today's call to review our fourth quarter and full year 2025 results. I will begin with an overview of our business performance in 2025 and summarize our progress against the Indivior Action Agenda. Pat will then provide a commercial update and discuss our priorities for sublocate. Finally, Ryan will review our financial performance, 2026 guidance, and then detail our capital deployment strategy. 2025 was a transition year for the company. Last July, we rolled out the Indivia Action Agenda to maximize the potential of our business, make a positive difference in the lives of people living with opioid use disorder, and to create value for our shareholders. We've made significant progress, including successfully completing phase one, generate momentum, and delivering against our financial commitments for 2025. Specifically, We improved our commercial execution and generated momentum for Sublocate, delivering record net revenue in 2025 of $856 mil...